NanoString Technologies Inc (NASDAQ:NSTG) was the target of a large decline in short interest during the month of March. As of March 29th, there was short interest totalling 961,404 shares, a decline of 28.0% from the March 15th total of 1,335,916 shares. Based on an average daily trading volume, of 956,532 shares, the days-to-cover ratio is currently 1.0 days. Currently, 3.1% of the shares of the stock are short sold.
Several research firms have recently issued reports on NSTG. Zacks Investment Research downgraded NanoString Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, March 12th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $35.00 price target on shares of NanoString Technologies in a research note on Friday, March 8th. BidaskClub downgraded NanoString Technologies from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 14th. Finally, ValuEngine raised NanoString Technologies from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 2nd. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $22.80.
In other news, SVP Mary Tedd Allen sold 5,000 shares of NanoString Technologies stock in a transaction on Monday, February 4th. The stock was sold at an average price of $22.57, for a total transaction of $112,850.00. Following the completion of the transaction, the senior vice president now owns 30,789 shares of the company’s stock, valued at approximately $694,907.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lifesciences Ii L.P. Clarus sold 2,000,000 shares of NanoString Technologies stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $21.62, for a total value of $43,240,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,088,141 shares of company stock valued at $43,896,351 in the last ninety days. Corporate insiders own 20.90% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc raised its stake in NanoString Technologies by 28.4% in the 3rd quarter. Legal & General Group Plc now owns 3,800 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 840 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its stake in NanoString Technologies by 430.9% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,893 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 7,218 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new position in NanoString Technologies in the 4th quarter valued at about $151,000. AQR Capital Management LLC acquired a new position in NanoString Technologies in the 3rd quarter valued at about $294,000. Finally, MetLife Investment Advisors LLC raised its stake in NanoString Technologies by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 17,579 shares of the biotechnology company’s stock valued at $313,000 after purchasing an additional 6,249 shares during the last quarter. 87.94% of the stock is owned by hedge funds and other institutional investors.
Shares of NSTG stock opened at $25.12 on Tuesday. NanoString Technologies has a twelve month low of $8.97 and a twelve month high of $31.14. The stock has a market capitalization of $807.46 million, a P/E ratio of -9.04 and a beta of 1.30. The company has a debt-to-equity ratio of 1.58, a current ratio of 3.05 and a quick ratio of 2.75.
NanoString Technologies (NASDAQ:NSTG) last announced its earnings results on Thursday, March 7th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.18). NanoString Technologies had a negative net margin of 72.52% and a negative return on equity of 252.59%. The firm had revenue of $30.03 million during the quarter. On average, analysts expect that NanoString Technologies will post -2.36 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.thestockobserver.com/2019/04/16/short-interest-in-nanostring-technologies-inc-nstg-decreases-by-28-0.html.
About NanoString Technologies
NanoString Technologies, Inc provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.
See Also: Systematic Risk
Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.